Pernix Therapeutics to Report First Quarter 2013 Financial Results on May 10, 2013 Management to Host a Conference Call on May 10, 2013 at 9:00 a.m. EST Business Wire THE WOODLANDS, Texas -- May 3, 2013 Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2013 financial results before the U.S. stock market opens on Friday, May 10, 2013 and has scheduled a conference call at 9:00 a.m. EST that day to discuss the financial results. The conference call will feature remarks by Cooper Collins, President and Chief Executive Officer, and Tracy Clifford, Vice President of Accounting and Corporate Controller. To participate in the conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874 (international). Participants can reference the passcode 50828084. Please dial in approximately 5 minutes prior to the call. The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website www.pernixtx.com. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast. A replay of the conference call will be available through May 17, 2013, at (855) 859-2056 domestic and (404) 537-3406 international. The passcode for the replay is 50828084. An online archive of the webcast will be available on the Company’s website for 30 days following the call. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals’ product line. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company also markets the branded product, SILENOR®, for the treatment of insomnia. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. Dr. Cocoa, a chocolate flavored cough and cold product, is in development for the U.S. OTC markets. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com. Contact: Pernix Therapeutics Holdings, Inc. Joseph T. Schepers, (800) 793-2145 ext. 3002 Director, Investor Relations firstname.lastname@example.org
Pernix Therapeutics to Report First Quarter 2013 Financial Results on May 10, 2013
Press spacebar to pause and continue. Press esc to stop.